Advanced Melanoma Patients May Benefit from PV-10

Cancer Connect

Among patients with melanoma that has spread to other areas of the skin or areas just beneath the skin, injection of the investigational drug PV-10 directly into the melanoma produced promising results in a Phase II clinical trial. These results were recently presented at the Melanoma 2010 Congress in Sydney, Australia.[1]

Melanoma is the most deadly type of skin cancer. Each year in the United States, there are roughly 68,000 new diagnoses of melanoma and 8,700 deaths from the disease. The most common sites of metastatic disease in melanoma are the lung, liver, bone, and brain. Melanoma can also spread to other areas of the skin (cutaneous metastases) or to areas just below the skin (subcutaneous metastases).

PV-10 is a drug that is being studied in clinical trials in cutaneous and subcutaneous melanoma metastases. PV-10 is a derivative of Rose Bengal, which is a staining agent that has been used to assess eye damage by ophthalmologists for decades. Preclinical studies have indicated that Rose Bengal may provide anticancer activity, and early studies in melanoma have indicated that PV-10 may be safe and active.[2] In addition, previous studies have suggested that PV-10 injected directly into melanoma lesions may also result in a bystander response in lesions that have not been injected.

In the current Phase II study, researchers evaluated 80 patients with advanced melanoma. Patients had PV-10 injected into one to 20 of their cutaneous, subcutaneous, or nodal metastases. Following initial treatment, patients could have new lesions or unresponsive lesions treated again at eight, 12, or 16 weeks with a final follow-up at 52 weeks. In addition, one to two lesions could be left untreated to assess for a bystander response.

Preliminary data on the first 40 patients were presented at the 2010 American Society of Clinical Oncology.[3] The current results are based on preliminary data from the entire study.

  • 49% of patients experienced an objective response (a reduction in detectable cancer). Among patients who responded to treatment, median progression-free survival was 11.7 months.
  • 71% of patients achieved stable disease or better in the lesions that were injected with PV-10. Some untreated lesions also responded, supporting the idea of a bystander effect.
  • Side effects were typically mild to moderate and included injection site pain, discoloration, and inflammation with only a small percentage of patients experiencing nausea, diarrhea, and difficulty swallowing.

The researchers concluded that PV-10 shows promise in patients with advanced melanoma with subcutaneous or cutaneous lesions. Additional studies are warranted to further define the role of this strategy.


[1] Agarwala AA, Thompson JF, Smithers BM, et al. Chemoablation of Metastatic Melanoma with PV-10.Presented at the Melanoma 2010 Congress. November 4-7, 2010. Sydney, Australia*.*

[2] Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res. 2008;18:405-11.

[3] Agarwala SS, Thompson JF, Smithers BM, et al. Chemoablation of metastatic melanoma with rose bengal (PV-10). J Clin Oncol. 2010;28:15. (Abstract 8534).

Copyright © 2018 CancerConnect. All Rights Reserved.